·8 min read·regulatory
After the FDA crackdown: the state of US compounded GLP-1 in May 2026
Five months after the FDA closed enforcement discretion on 503A and 503B compounded tirzepatide and semaglutide, the US compounded-GLP-1 landscape has consolidated, contracted, and fragmented. The April 30 scorecard recap captured the snapshot. This is what changed in the four weeks after.